Announcements Trials
Browse Landscape

Phase

Phase 3 2

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 5Sarcoma 2Myeloid 2Plasma cell 1Genitourinary 1Dermatologic 1

Conditions

Neoplasm Metastasis 2Gastrointestinal Stromal Tumors 2

Interventions

Doxorubicin 40Radiotherapy 30Ifosfamide 28Vincristine 27Cyclophosphamide 24Imatinib Mesylate 20Etoposide 20Dactinomycin 14Radiation 13Filgrastim 11Temozolomide 9Sunitinib 9Trabectedin 8Methotrexate 8Specimen Handling 7Magnetic Resonance Spectroscopy 6Granulocyte Colony-Stimulating Factor 6Chemotherapy, Adjuvant 6pazopanib 5nilotinib 5Zoledronic Acid 5Neoadjuvant Therapy 5Irinotecan 5Cisplatin 5Carboplatin 5X-Rays 4Vinorelbine 4Topotecan 4Surgical Procedures, Operative 4Procarbazine 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × masitinib × Sarcoma × Clear all
NCT00812240 2023-02-01

Masitinib in First Line Treatment of Gastro-Intestinal Stromal Tumor (GIST)

AB Science

Phase 3 Terminated
335 enrolled
GastrointestinalSarcoma

Neoplasm Metastasis, Gastrointestinal Stromal Tumors

NCT01694277 2020-12-08

Masitinib in Patients With Gastrointestinal Stromal Tumour After Progression With Imatinib

AB Science

Phase 3 Completed
258 enrolled
GastrointestinalSarcoma

Neoplasm Metastasis, Gastrointestinal Stromal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡